| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.39▼ | 8.12▲ | 8.10▲ | 7.79▲ | 8.18▲ |
| MA10 | 8.30▲ | 8.02▲ | 7.86▲ | 8.02▲ | 7.65▲ |
| MA20 | 8.14▲ | 7.78▲ | 7.73▲ | 7.92▲ | 8.01▲ |
| MA50 | 8.03▲ | 7.72▲ | 7.91▲ | 7.41▲ | 5.84▲ |
| MA100 | 7.82▲ | 7.92▲ | 8.02▲ | 8.05▲ | 5.33▲ |
| MA200 | 7.71▲ | 7.99▲ | 7.78▲ | 5.94▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.026▲ | 0.065▲ | 0.106▲ | -0.044▼ | -0.062▼ |
| RSI | 72.956▲ | 73.649▲ | 67.808▲ | 55.863▲ | 56.479▲ |
| STOCH | 89.604▲ | 86.091▲ | 93.656▲ | 30.541 | 60.452 |
| WILL %R | -20.000▲ | -10.204▲ | -7.042▲ | -45.494 | -42.678 |
| CCI | 56.352 | 215.288▲ | 132.356▲ | 19.497 | 69.153 |
|
Sunday, October 26, 2025 07:18 AM
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis ...
|
|
Friday, October 24, 2025 08:48 PM
・The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris. ・The company said that once daily oral 50 mg ...
|
|
Tuesday, October 21, 2025 05:00 PM
Fintel reports that on October 22, 2025, Clear Street initiated coverage of Sagimet Biosciences (NasdaqGM:SGMT) with a Buy recommendation. Analyst Price Forecast Suggests 237.60% Upside As of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/11/25 | 7.89 | 8.455 | 7.74 | 8.35 | 483,107 |
| 07/11/25 | 7.53 | 7.67 | 7.0201 | 7.52 | 488,874 |
| 06/11/25 | 7.76 | 8.06 | 7.68 | 7.69 | 333,550 |
| 05/11/25 | 7.63 | 7.935 | 7.5302 | 7.77 | 405,935 |
| 04/11/25 | 8.05 | 8.1444 | 7.61 | 7.61 | 645,419 |
| 03/11/25 | 8.48 | 8.624 | 8.03 | 8.06 | 386,900 |
| 31/10/25 | 8.14 | 8.60 | 8.14 | 8.52 | 313,047 |
| 30/10/25 | 8.21 | 8.36 | 8.05 | 8.14 | 352,001 |
| 29/10/25 | 8.20 | 8.5699 | 8.06 | 8.33 | 452,652 |
| 28/10/25 | 8.56 | 8.66 | 8.02 | 8.24 | 554,164 |
|
|
||||
|
|
||||
|
|